When doctors turn to the new opioid to save lives
Allena Pharmaceuticals announced on Monday that it had received approval to sell a new opioid for the treatment of opioid addiction, a move that could help it get back on track.
The company’s chief executive, Paul DeWitt, said the drug, Zopiclone, has a lower chance of addiction than other prescription opioids, which are now widely available.
Zopiclones are not approved for the use in the United States for treating opioid addiction.
But the drug was approved by the U.S. Food and Drug Administration and has a higher potential for abuse and diversion than other opioids, such as OxyContin, according to the FDA.
“It’s a very different situation than other drugs, like OxyContin,” DeWatt said in an interview.
“But this is something that is available to people and is very effective at treating chronic pain.
And we want to continue to develop it.”
DeWitt said Zopiclanone, which costs about $70 a day, is a safe alternative to OxyContin.
He said it has the advantage of being a “pre-opioid” type of drug that does not contain opioids.
But it does not have a similar effect on the body, which has not yet responded to opioids.ZOPLAINE will be marketed under the brand name OxyContin and will be available through retail pharmacies and pharmacies that carry generic opioids.
It will be sold by Allena Pharma, a company that also makes the pain reliever hydrocodone and is part of the American Medical Group, a drug-company conglomerate that is owned by Pfizer Inc. and includes Abbott Laboratories, AstraZeneca Plc, CVS Caremark Corp and Humana Inc.
In the United Kingdom, where OxyContin has been on the market since 2005, the drug is now available over the counter under the name Opana.
It is also available over-the-counter in the Netherlands and in Canada.
The United States is the only country that does have prescription opioids available over that type of a drug called OxyContin for pain.
The Drug Enforcement Administration is now investigating whether OxyContin abuse in the U and Europe may have been responsible for a surge in overdoses in the country in 2016.
The drug is also on the U, UK and Australia’s list of banned substances.
In an interview, DeWotts said Allena would not make a profit on the drug but will earn about $50 million on the deal.
Allena was the first company to receive FDA approval to market Zopiclonone, a generic version of the brand, for the acute pain of chronic pain, which is the most common form of pain.